New drug for lung cancer

The US Food and Drug Administration (FDA) has approved the drug Abraxane (paclitaxel protein-bound) in combination with the drug carboplatin for the treatment of small cell lung cancer.

Abraxane was first approved by the FDA to treat breast cancer in 2005.



The FDA said that in a new clinical trial, conducted on 1,038 patients with non-small cell lung cancer, the most common side effects in patients taking Abraxane included anemia, hair loss, nausea, fatigue, loss of appetite, rash and skin irritation.

Abraxane is manufactured by Celgene Corporation, headquartered in Summit, New Jersey, USA.

According to Women Online/Goodhealth - NT